A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide
Categories (click each to see list of all clinical trials associated with that category): Myeloma/Plasma Cell Dyscrasia (ONC)
Current Status: Open
Phase: III (Cancer Control)
Principal Investigator: Wildes, Tanya
Contact Information:
Marnee Strege
+1 402-559-8155
marnee.strege@unmc.edu
Eligibility: https://clinicaltrials.gov/study/NCT06208150?term=NCT06208150&rank=1#participation-criteria
Summary
Primary
To compare the efficacy of either Tal-P or Tal-Tec with EPd or PVd
Secondary
To further compare the efficacy of either Tal-P or Tal-Tec with EPd or PVd
To assess the safety and tolerability of Tal-P and Tal-Tec